(This Feb 6. story has been corrected to show the damages are according to an expert report, and not estimated by IHH's unit.
IHH Healthcare's Singaporean subsidiary, Northern TK Venture, has raised its damage claim against Japan's Daiichi Sankyo in a Tokyo court to JPY 199.8 billion amid a legal battle over a stalled open ...
The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...
Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials Individual patient data of neoadjuvant RCTs ...
Hiroyuki Okuzawa, current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with ...
Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in oncology, driven by ENHERTU’s market leadership and robust sales growth across regions. Despite regulatory delays for Datroway ...
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1.
Two oncology treatments also received CHMP’s blessing. AstraZeneca and Daiichii Sankyo’s antibody-drug conjugate (ADC) Datroway was recommended for certain patients with unresectable or ...
(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...
TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback